Business News

WAVE Life Sciences Starts Clinical Trials

images (11)

Biotech company WAVE Life Sciences (WVE) said Monday it has initiated its PRECISION-HD program, which includes phase 1b and 2a clinical trials evaluating WVE-120101 and WVE-120102, respectively, for patients with Huntington’s disease (HD). “Wave’s PRECISION-HD program is the first to target the underlying cause of Huntington’s disease with an allele-specific approach,” said Michael Panzara, neurology franchise lead of Wave Life Sciences. “Obtaining approvals to initiate these global studies as part of our first clinical program marks an important milestone for Wave. More importantly, these investigational compounds have the potential to address a critical unmet need for the HD patient community where no disease-modifying treatments are currently approved.”